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Pompe disease is an inherited neuromuscular disorder caused by a genetic defi-
ciency of acid-glucosidase-alpha (GAA). The clinical symptoms of Pompe disease
include progressive weakness, respiratory failure, and ventricular hypertrophy.
Enzyme replacement therapy has been shown to ameliorate these symptoms.
Cardiomyocytes derived from patient/disease-specific iPS cells (iPS-CMs) have
been used for pathophysiological analyses, drug screening, and cell therapy. Our
research goal was to generate cardiomyocytes that can be differentiated from gene-
corrected Pompe disease-specific iPS cells.
We obtained iPSC (TkDA3-4) generated from human dermal fibroblasts
[1]. GAA was cloned into cDNA expressing third-generation lentiviral vectors
(CS2-EF1α-GAA). To assess the transfection efficacy, Venus, a YFP variant
protein, was also cloned into the vector (CS2-EF1α-Venus). Then, we transfected
lentiviral vectors containing GAA to iPSCs at three different concentrations to
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determine the optimized titer for gene correction. We showed that dose-dependent
expression of both GAA and Venus was observed in iPSCs, even though the
expression levels were relatively low compared to HEK293A cells.
Cardiomyocyte differentiation of iPS cells is the most important procedure for
replicating the disease hallmarks of Pompe disease. In fact, there is no single best
protocol for obtaining cardiomyocytes derived from iPS cells. The functional
assessment of iPSC-derived cardiomyocytes is another critical aspect of our
research. The differences between the function of iPSC-derived cardiomyocytes
obtained from normal control cells and those obtained from Pompe disease cells
should therefore be strictly evaluated in order to thoroughly discuss the efficacy of
gene therapy for iPSC (Fig. 48.1).
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Fig. 48.1 Gene transfer to HEK293A cells and TkDA3-4. Dose-dependent expressions of GAA
and Venus were observed in each cell line
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The images or other third party material in this chapter are included in the work’s Creative
Commons license, unless indicated otherwise in the credit line; if such material is not included in
the work’s Creative Commons license and the respective action is not permitted by statutory
regulation, users will need to obtain permission from the license holder to duplicate, adapt or
reproduce the material.
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